- Home
- CNOB vs DMRA Comparison
CNOB vs DMRA Comparison
Compare CNOB & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOB | DMRA |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNOB | DMRA |
|---|---|---|
| Price | $31.27 | $23.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $31.25 | ★ $43.00 |
| AVG Volume (30 Days) | 269.8K | ★ 439.2K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ 121.48 |
| EPS | ★ 1.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.85 | N/A |
| Revenue Next Year | $7.27 | N/A |
| P/E Ratio | $20.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.20 | $16.50 |
| 52 Week High | $34.14 | $34.89 |
Technical Indicators
Market Signals| Indicator | CNOB | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 32.49 |
| Support Level | $30.87 | $22.71 |
| Resistance Level | $33.95 | $27.40 |
| Average True Range (ATR) | 0.56 | 2.04 |
| MACD | -0.01 | -0.65 |
| Stochastic Oscillator | 31.29 | 8.34 |
Price Performance
Historical ComparisonAbout CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.
About DMRA Damora Therapeutics Inc. Common Stock
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.